Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Abstract
Iron overloading disorders linked to mutations in ferroportin have diverse phenotypes in vivo, and the effects of mutations on ferroportin in vitro range from loss of function (LOF) to gain of function (GOF) with hepcidin resistance. We reviewed 359 patients with 60 ferroportin variants. Overall, macrophage iron overload and low/normal transferrin saturation (TSAT) segregated with mutations that caused LOF, while GOF mutations were linked to high TSAT and parenchymal iron accumulation. However, the pathogenicity of individual variants is difficult to establish due to the lack of sufficiently reported data, large inter-assay variability of functional studies, and the uncertainty associated with the performance of available in silico prediction models. Since the phenotypes of hepcidin-resistant GOF variants are indistinguishable from the other types of hereditary hemochromatosis (HH), these variants may be categorized as ferroportin-associated HH, while the entity ferroportin disease may be confined to patients with LOF variants. To further improve the management of ferroportin disease, we advocate for a global registry, with standardized clinical analysis and validation of the functional tests preferably performed in human-derived enterocytic and macrophagic cell lines. Moreover, studies are warranted to unravel the definite structure of ferroportin and the indispensable residues that are essential for functionality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The two-dimensional (2D) structure of ferroportin protein adapted from Liu and Wallace [6,56], revealing 12 transmembrane helices and six extracellular and five intracellular segments. All the variants described in this review are shown as hepcidin-resistant (pink), hepcidin-sensitive or neutral (purple) and hepcidin conflicting/uncertain/unknown (red) GOF variants (squares). and hepcidin resistant (light blue), hepcidin sensitive (dark blue), and hepcidin conflicting-uncertain-unknown (green) LOF variants (dots), or non-classified variants (grey asterix).](https://figures.cochat.ai/paper-figures/372b17ce55994870988faf6b6062f0f6/twenty-years-of-ferroportin-disease-a-review-or-an-update-of-published-clinical-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A confluence of human genetics studies and structure-function evaluations have identified key regions of FPN important in hepcidin regulation 7,19-22 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutation of several residues within the intracellular gate leads to FPN loss of function in ferroportin disease, highlighting the importance of the gate in coordinating the conformational steps necessary for iron efflux 19,28 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 2×
“To assess co-segregation in multiple affected family members, the simplified method of segregation analysis (SISA) was applied [22,23] and classified according to recent recommendations to define co-segregation to fit the guidelines of the American College of Medical Genetics and Genomics and the Association for Molec…”
MethodHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 2×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
WHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469 · cited 3×
“For the two-dimensional (2D) model (Figure 3), we adapted the structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used Pharmaceuticals 2019, 12, 132 17 of 29 the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet Another Scie…”
MethodPositional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field
Krieger, E., Koraimann, G., & Vriend, G. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10104 · Cited by 1,514 · cited 3×
“For the two-dimensional (2D) model (Figure 3), we adapted the structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used Pharmaceuticals 2019, 12, 132 17 of 29 the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet Another Scie…”
MethodMcKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267 · cited 1×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
BackgroundSerum ferritin: Past, present and future
Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M., & Torti, S. V. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.03.011 · Cited by 879 · cited 1×
“This corroborates the notion that high TSAT facilitates parenchymal iron deposition, which is considered to be more toxic than macrophage iron overload [154].”
BackgroundMuckenthaler, M. U., Galy, B., & Hentze, M. W. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155521 · Cited by 701
Research works printed but not linked: 4
- 2015, A Pediatric Case Report of Ferroportin Disease, J. Pediatr. Gastroenterol. Nutr., 63, e205
- Relvas, 2009, Novel human pathological mutation: Gene Symbol: SLC40A1; Disease: Haemochromatosis, type IV, Hum. Genet., 125, 338
- Muehlenberg, 2014, [Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease)], Z. Gastroenterol., 52, 1075
- Caetano, G., Relvas, L., Bento, C., Silveira, M.P., and Ribeiro, L. (2009, January 7–11). Atypical iron deficiency anemia—Association of two new mutations in ferroportin and TMPRSS6 genes. Proceedings of the International BioIron Society Annual Meeting, Porto, Portugal.
Cited by
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · Nature · doi:10.1038/s41586-020-2668-z · Cited by 344
Hemochromatosis classification: update and recommendations by the BIOIRON Society
Girelli, D., Busti, F., Brissot, P., Cabantchik, I., Muckenthaler, M. U., & Porto, G. (2022) · Blood · doi:10.1182/blood.2021011338 · Cited by 187
Structural basis of ion transport and inhibition in ferroportin
Pan, Y., Ren, Z., Gao, S., Shen, J., Wang, L., Xu, Z., Yu, Y., Bachina, P., Zhang, H., Fan, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19458-6 · Cited by 81
Interplay of oxidative stress and antioxidant mechanisms in cancer development and progression
Jomová, K., Alomar, S. Y., Valko, R., Fresser, L., Nepovimová, E., Kuča, K., & Valko, M. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04146-5 · Cited by 130
“Ferroportin is a transmembrane protein that transports iron from the intracellular space to the extracellular environment via the iron chaperone poly (RC)-binding protein 2 (PCBP2), which has been found to have ambiguous functions in a variety of cancers (Vlasveld et al. 2019).”
Metadata
- Authors
- Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W.
- Affiliations
- Bronovo Hospital (NL)
- Radboud University Medical Center (NL)
- Liver Diseases Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
- Molecular Genetics Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
- University of Oxford (GB)
- Corresponding author
- Swinkels, Dorine W.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-09-09
- Volume
- 12
- Issue
- 3
- Pages
- 132
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789780
- OpenAlex
- W2972637634
- Cited by
- 57
- References
- 150
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 9 · 2022: 1 · 2021: 14 · 2020: 9 · 2019: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MC_UU_00008/10)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- ferroportin disease, iron overload, hereditary hemochromatosis, loss-of-function mutations, gain-of-function mutations, transferrin saturation, variant pathogenicity, functional assays, in silico prediction models, patient registry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features. https://app.cochat.ai/papers/10.3390/ph12030132
- The paper
- Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W. (2019). Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features. Pharmaceuticals. https://doi.org/10.3390/ph12030132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.